MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/13543784.2021.1916913

Медицинская библиотека · Expert opinion on investigational drugs · 2021

Dementia with Lewy bodies: emerging drug targets and therapeutics.

Pope Evans D, Cordes Laura, Shi Jiong, Mari Zoltan, Decourt Boris, Sabbagh Marwan Noel

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Introduction

Dementia with Lewy bodies (DLB) is characterized by the toxic accumulation of α-synuclein protein inside neural cells; this results in neurodegeneration which is clinically accompanied by behavioral and psychological changes. DLB shares features with Parkinson's disease (PD) and Parkinson's disease dementia (PDD), but also overlaps neurochemically and pathologically with Alzheimer's disease. Symptomatic treatments for LBD differ in their effectiveness while disease-modifying and curative approaches are much needed.Areas covered: We explore emerging therapeutics for DLB through the lens of repurposing approved drugs and survey their potential for disease modifying actions in DLB. Given the complexity of DLB with multiple pathologies, potential therapeutic targets that could affect Lewy body pathology, or metabolism or neurotransmitters or immunomodulation were surveyed. We queried PubMed and ClinicalTrials.gov searches 2017-2020.Expert opinion: DLB is not simply aredux ofAD or PD; hence, treatments should not be exclusively duplicative ofAD or PD directed treatments. This opens amyriad of possibilities for therapeutic approaches that are disease specific or repurposed.

Для цитирования: Pope Evans D, Cordes Laura, Shi Jiong, Mari Zoltan, Decourt Boris, Sabbagh Marwan Noel. Dementia with Lewy bodies: emerging drug targets and therapeutics.. Expert opinion on investigational drugs. 2021. DOI: 10.1080/13543784.2021.1916913.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.